tbuckley/cabot-search huggingface dataset:
Survival prognostic value of obesity in localized triple negative breast cancer in Peruvian women.
Authors: Gabriel Antonio De la Cruz Ku, Daniel Enriquez, Zaida Morante, Eduardo Eyzaguirre, Renato Luque, Margiory Fernandez, Silvia P. Neciosup, Henry Leonidas Gomez
Journal: Journal of Clinical Oncology (2017)

e12100 Background: Obesity has been associated with development of TNBC, but its prognostic value on outcomes is still controversial. The aim of this study was to describe clinicopathological characteristics and compare Disease Free Survival (DFS) and Overall Survival (OS) according to obesity status. Methods: We performed a retrospective study on 1415 patients diagnosed with TNBC, admitted during the 2000-2014 period at the Instituto Nacional de Enfermedades Neoplasicas. We divided TNBC patients in two groups based on WHO classification: Non-obese (BMI: 18.5-29.9) and Obese women (BMI≥30). The survival differences were assessed with log-rank test and prognostic factors were then investigated by Cox regression analysis. Results: The median age was 49.5years (19-89years). Of all registered patients, 389 (27.5%) had obesity and 45% were premenopausal, however obese women were predominantly postmenopausal (55%, p &lt; 0.001). Breast-ovarian cancer family background was present in 16.9%. T3-T4 tumors were 46.1% while 58.8% had nodal involvement. Neoadjuvant treatment was administered to more than a third patients (37.2%), and 430 out of 1415 had conservative surgery. With a median of follow-up of 5.1 years, there were 274 (18.9%) local and 402 (27.8%) distant recurrences registered without differences between groups. In obese women, 5-year DFS was 63%, while non-obese was 65% (HR: 1.10, 95%CI: 0.96-1.4, p = 0.35). 5-year OS, was 65 and 64% in obese and non-obese, respectively (HR: 0.93, 95%CI: 0.8-1.1, p = 0.43). Nevertheless, no significant impact was reached on outcomes at uni or multivariate analysis. In multivariate cox regression analysis, neoadjuvant chemotherapy was related to a better prognosis in DFS and OS; in addition, conservative surgery was a protector factor of OS. On the other hand, T4 and nodal involvement were statistically significant to worse DFS and OS; besides premenopausal status and family background affected the DFS and OS, respectively. Conclusions: In this population of TNBC patients, we did not find negative prognostic impact of obesity in terms of DFS and OS. Others potential factors are needed to be explored in futures studies.
Treatment patterns and patient profiles for docetaxel-based adjuvant chemotherapy in early-stage breast cancer in China: A pooled analysis of four observational studies.
Authors: Binghe Xu, Zhimin Shao, Shui Wang, Zefei Jiang, Xichun Hu, Xiaohua Zhang, Xi Ru Li, Jinping Liu, Mengquan Li, Shu Wang
Journal: Journal of Clinical Oncology (2017)

e12017 Background: Adjuvant docetaxel-based chemotherapy is frequently used for operable breast cancer. This study investigated the patterns of use of docetaxel (T) in real-life clinical practice in China. Methods: This retrospective pooled analysis included female Chinese adults (≥18 years) with operable breast cancer treated with docetaxel-based adjuvant chemotherapy enrolled in the Asia-Pacific Breast Initiatives (APBI) I (2006-2008) and II (2009-2011) registries, and two Chinese observational studies; BC STATE (2011-2014) and BC Local Registry (2007-2010). Patients with metastatic disease were excluded. The primary endpoint was assessment of treatment patterns and patient profiles. Patient profiles for treatment regimen selection were investigated using regression analysis. Results: Data from 3020 patients were included. The most commonly used regimen was docetaxel/anthracycline combination (n=1421 [47.1%]; of whom 52.0% received T/epirubicin (E)/cyclophosphamide (C)), followed by docetaxel/other (n=705 [23.3%]; of whom 72.8% received TC), docetaxel/anthracycline sequential (n=447 [14.8%]; of whom 40.9% and 39.6% received 5-Fu/EC-T and EC-T), and ‘Other’ (n=447 [14.8%]; of whom 91.5% received T). Multivariate regression analysis revealed a significant association between selection of docetaxel/anthracycline combination and patient weight, menopausal status, and estrogen receptor and HER-2 status (Table). Conclusions: Data from real clinical practice show docetaxel/anthracycline combination is the most commonly used docetaxel-based adjuvant therapy for operable breast cancer in China; of which TEC is the most popular specific regimen. Several patient profile factors were significantly associated with the selection of docetaxel/anthracycline combination. [Table: see text]
Abstract 14923: Comparative Performance of ATRIA, CHADS 2 , R 2 CHADS 2 and CHA 2 DS 2 -VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: A Nationwide Cohort sSudy in Korea
Authors: Daehoon Kim, Pil-Sung Yang, Tae-Hoon Kim, Jae-Sun Uhm, Hui-Nam Pak, Moon-Hyoung Lee, Boyoung Joung
Journal: Circulation (2016)

Background:  Recently, the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) score, was developed and validated for stroke risk stratification for atrial fibrillation (AF). This study compared predictive ability of the ATRIA, CHA 2 DS 2 -VASc, CHADS 2 , and R 2 CHADS 2  scores and their implications for anticoagulant treatment in patients with non-valvular AF.   Methods:  Patients with non-valvular AF not using oral anticoagulants (OACs) were included from 506,806 adults in prospective cohort data collected by the National Health Insurance Service in Korea. Patients were followed from AF diagnosis until occurrence of ischemic stroke, prescription of OAC, death, or the study’s end. Independent predictors of ischemic stroke were identified and the c-index and net reclassification improvement were calculated.   Results:  During 14,430 person-years of follow-up, we observed 188 ischemic strokes. Annualized stroke rate was 1.3%. The C statistics for the full-range ATRIA score was 0.77 (95% confidence interval [CI]: 0.74 to 0.80), significantly better than the CHA 2 DS 2 -VASc of 0.74 (95% CI: 0.70 to 0.77), the CHADS 2  of 0.74 (95% CI: 0.71 to 0.78), and the R 2 CHADS 2  of 0.74 (95% CI: 0.70 to 0.78). The ATRIA score also improved the net reclassification index by 34% compared with CHA 2 DS 2 -VASc score, 17% compared with CHADS 2  score, and 6.9% compared with R 2 CHADS 2  score. Among 2,390 patients categorized as low-risk on the basis of an ATRIA score of 0 to 5, the patients were categorized as low, moderate, and high-risk on the basis of CHA 2 DS 2 -VASc score, and annual stroke rates ranged from 0.13% to 0.56%.   Conclusions:  The ATRIA score performed better in the Korean national cohort. It more accurately identified low-risk patients than the CHA 2 DS 2 -VASc score, which assigned these patients to higher-risk categories. Such reclassification of stroke risk could prevent overuse of anticoagulants in very low stroke risk patients with AF.
Sixty seconds on . . . #crazysocks4docs
Authors: Paul Smith
Journal: BMJ (2017)

Not quite, it’s more of a social media trend than a fashion trend. Last week images of doctors in Australia wearing odd and unusual socks went viral on Twitter.

It’s part of a campaign to get the medical profession to talk about mental illness. There is still a widespread view that a doctor seeking help for mental health problems is on a fast track to wrecking their career. The doctors behind the campaign say that in a profession with an ingrained …
Non-adherence behaviors among young women on adjuvant endocrine therapy for breast cancer.
Authors: Johanna Wassermann, Shari I. Gelber, Shoshana M. Rosenberg, Kathryn Jean Ruddy, Rulla M. Tamimi, Lidia Schapira, Virginia F. Borges, Steven E. Come, Ann H. Partridge
Journal: Journal of Clinical Oncology (2017)

526 Background: Young age at diagnosis (dx) is a predictor of worse prognosis in patients (pts) with luminal breast cancer (BC). Poorer adherence to endocrine therapy (ET) among younger women may contribute to this disparity. Aim: To assess non-adherent behaviors and associated factors among young women with stage 1-3 hormone receptor (HR)+ BC taking ET. Methods: This study is a part of a multi-center, prospective cohort of pts with dx of BC at or under age 40. On a survey 30 months after dx, among pts reporting taking ET, adherence was measured using a 3-item Likert-type scale (Do you ever forget to take your ET? If you feel worse when you take your ET, do you stop taking it? Did you take your ET exactly as directed by your doctor?). Pts reporting any non-adherent behavior during the last 3 months were classified as non-adherers. Variables with a p-value &lt;0.20 were included in a multivariate logistic model. Results: Among361 pts eligible for this analysis, 174 (48%) reported some non-adherent behaviors in the last 3 months; 56 (16%) moderate or greater non-adherent behaviors. None of the studied variables was associated with non-adherent behaviors (table). Conclusions: Non-adherent behaviors to ET are present in almost half of the young women with HR+ BC. Further analyses of explanatory factors and impact of non-adherence are required to understand and potentially improve this problem. [Table: see text]
Vascular endothelial growth factor protein expression is associated with a poor prognosis in patients with cutaneous extranodal natural killer/T‐cell lymphoma
Authors: W.J. Lee, Y.J. Kim, Y.J. Lee, C.H. Won, S.E. Chang, J.H. Choi, M.W. Lee
Journal: British Journal of Dermatology (2017)

Vascular endothelial growth factor (VEGF) can stimulate angiogenesis and lymphangiogenesis, which are crucial processes in the growth and metastasis of tumour cells.1,2 The immunohistochemical status of VEGF protein expression in tumour tissue of extranodal NK/T-cell lymphoma (ENKTL) has not yet been evaluated. Herein, we investigated VEGF protein expression, as well as its prognostic value in cutaneous ENKTL patients.

This article is protected by copyright. All rights reserved.
Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry
Authors: Paul C. Mayor, Kevin H. Eng, Kelly L. Singel, Scott I. Abrams, Kunle Odunsi, Kirsten B. Moysich, Ramsay Fuleihan, Elizabeth Garabedian, Patricia Lugar, Hans D. Ochs, Francisco A. Bonilla, Rebecca H. Buckley, Kathleen E. Sullivan, Zuhair K. Ballas, Charlotte Cunningham-Rundles, Brahm H. Segal
Journal: Journal of Allergy and Clinical Immunology (2017)

We evaluated the overall and site-specific incidence of cancer in subjects with primary immunodeficiency diseases (PIDD) enrolled in the United States Immune Deficiency Network (USIDNET) registry compared with age-adjusted cancer incidence in the Surveillance, Epidemiology and End Results Program (SEER) database.
Reduction of Fallout Radiation Hazards in Health Installations
Authors: W R WATERS
Journal: JAMA (1963)

The purpose of this paper is to provide guidance for Canadian hospital medical directors in planning the provision of protection for their patients and staff against gamma radiation hazard from nuclear war. The implications of the distribution of fallout in Canada are that the probability of exposures in excess of 600 r in the period "96 hours after fallout" is high in Southern Ontario and Quebec but low in the western provinces and in the North. All hospitals should have a shielding capacity; for many, this will entail structural alterations. The aim would be to provide a protective factor of 100 or better, together with necessary standards of habitability. The engineering significance of the recommendations is discussed.
Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial.
Authors: Jens Bodo Huober, Eileen McCormick Holmes, Jose Baselga, Evandro De Azambuja, Michael Untch, Debora Fumagalli, Severine Sarp, Istvan Lang, Ian E. Smith, Frances M. Boyle, Binghe Xu, Christophe Lecocq, Lorena De La Pena, Christian Jackisch, Richard D. Gelber, Martine J. Piccart-Gebhart, Serena Di Cosimo
Journal: Journal of Clinical Oncology (2017)

512 Background: In the neoadjuvant NeoALTTO trial dual HER2 blockade with lapatinib (L) plus trastuzumab (T) combined with weekly paclitaxel significantly increased the pathologic complete response rate (pCR) compared with either anti-HER2 agent alone plus paclitaxel. At first analysis pts with pCR had a better event free survival (EFS) and overall survival (OS) after median follow-up of 3.84 yrs. Methods: 455 pts with operable HER2-positive breast cancer were randomized to receive either L (n=154) 1500mg/day, T 4mg/kg loading dose followed by 2mg/kg/wk (n=149) or L 1000mg/day plus T (n=152) for 6 weeks followed by the assigned anti-HER2 treatment combined with paclitaxel weekly x 12. Following surgery pts received 3 cycles fluorouracil, epirubicin and cyclophosphamide q 3 weeks. The assigned anti-HER2 treatment was continued for 34 weeks thereafter. Primary endpoint was pCR (ypT0/is), secondary endpoints were EFS and OS and the association between pCR and OS analyzed by landmark analysis 30 weeks after randomization. Median follow-up was 6.7 years. Results: 6-yrs EFS rate was 67%/ 67%/74% with L/T/TL, respectively (L vs T HR 0.98 [95% CI 0.64–1.51] p=0.93; TL vs T HR 0.81 [95% CI 0.52–1.26] p=0.35). In the hormone receptor negative group 6- yrs EFS rate was 61%/ 63%/74% for the 3 groups, respectively (L vs T HR 1.09 [95% CI 0.61–1.95] p=0.76; TL vs T HR 0.81 [95% CI 0.44–1.51] p=0.52). OS at 6 yrs was 82%/79%/85% for L, T and TL, respectively (L vs T: HR 0.85 [95% CI 0.49-1.46] p=0.56; TL vs T HR 0.72 [95% CI 0.41-1.27] p=0.26). In landmark analyses, pts with a pCR had significantly higher 6-yrs EFS (77% /65%) and OS (89% /77%) compared to those without pCR, both overall and for the hormone receptor negative cohort. Conclusions: The updated results of the NeoALTTO study confirm the sustained survival benefits for pts who achieve a pCR. EFS and OS after 6 yrs did not differ significantly between the 3 treatment groups. The combination of T and L showed numerically higher EFS compared to T, especially in the hormone-receptor negative group. Clinical trial information: NCT00553358. [Table: see text]
Effects of adipose stem cell sheets on colon anastomotic leakage in an experimental model: Proof of principle
Authors: Panithi Sukho, Geesien S.A. Boersema, Abigael Cohen, Nicole Kops, Johan F. Lange, Jolle Kirpensteijn, Jan Willem Hesselink, Yvonne M. Bastiaansen-Jenniskens, Femke Verseijden
Journal: Biomaterials (2017)
When to Adjust for Potentially Confounding Variables—Reply
Authors: Maki Inoue-Choi, Neal D. Freedman
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Treatment outcomes of MDR-TB and HIV co-infection in Europe
Authors: Cecile Magis-Escurra, Gunar Günther, Christoph Lange, Sofia Alexandru, Neus Altet, Korkut Avsar, Didi Bang, Raisa Barbuta, Graham Bothamley, Ana Ciobanu, Valeriu Crudu, Manfred Davilovits, Martin Dedicoat, Raquel Duarte, Gina Gualano, Heike Kunst, Wiel de Lange, Vaira Leimane, Anne-Marie McLaughlin, Inge Muylle, Veronika Polcová, Christina Popa, Rudolf Rumetshofer, Alena Skrahina, Varvara Solodovnikova, Victor Spinu, Simon Tiberi, Piret Viiklepp, Frank van Leth
Journal: European Respiratory Journal (2017)

The ongoing HIV epidemic and the increasing number of patients with drug-resistant tuberculosis (TB) are seriously hampering global TB-control activities, including those in the World Health Organization (WHO) Region Europe. Overall, the prevalence of HIV co-infection in TB patients increased from 3.4% in 2008 to 8% in 2014 in the region [1]. The prevalence of multidrug-resistant (MDR)-TB (drug resistance against at least isoniazid and rifampicin) reported for Europe – 15% in newly diagnosed TB patients and 48% in previously treated TB patients – is the highest in the world [1]. HIV-positive patients with MDR-TB demonstrate a very low proportion of relapse-free cure <http://ow.ly/r9sk30bqLBP> The authors thank Bram Prins (Amsterdam Institute of Global Health and Development, Amsterdam, The Netherlands) and Nelleke Smitsman (Research Center Borstel, Sülfeld, Germany) for valuable data managing support.
Erratum: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome (Nature Medicine (2005) 11 (791-796))
Authors: Takaji Wakita, Thomas Pietschmann, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Zijiang Zhao, Krishna Murthy, Anja Habermann, Hans Georg Kräusslich, Masashi Mizokami, Ralf Bartenschlager, T. Jake Liang
Journal: Nature Medicine (2005)
A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.
Authors: Xavier B. Pivot, Igor Bondarenko, Mikhail Dvorkin, Ekaterina Trishkina, Jin-Hee Ahn, Seock-Ah Im, Tomasz Sarosiek, Sanjay Chattopadhyay, Marek Wojtukiewicz, Vladimir Moiseyenko, Yaroslav V. Shparyk, Maximino De Guzman Bello, Vladimir Semiglazov, Sujeong Song, Jae Yun Lim
Journal: Journal of Clinical Oncology (2017)

509 Background: SB3, a proposed biosimilar to the originator trastuzumab (TRZ), demonstrated similarity to its originator in terms of biological activities and pharmacokinetic (PK) equivalence. This study compared SB3 to TRZ in terms of efficacy, safety, PK, and immunogenicity in patients treated by neoadjuvant therapy for HER2 positive early breast cancer (NCT02149524). Methods: Phase III, randomized, double blind, multicenter study compared neoadjuvant SB3 or TRZ for 8 cycles concurrently given with chemotherapy (docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide). Then patients underwent surgery followed by 10 cycles of SB3 or TRZ. The primary endpoint was breast pathologic complete response (bpCR) rate. Equivalence was declared if the 90% confidence interval (CI) of the ratio or the 95% CI of the difference of the bpCR rates in the per-protocol set (PPS) were contained within the pre-defined equivalence margins (0.785, 1.546) and (-13%, 13%), respectively. Secondary endpoints were total pathologic complete response (tpCR), overall response rate (ORR), event-free survival, PK, immunogenicity, and safety. Results: 800 patients were included in PPS. The bpCR rates were 51.7% for SB3 and 42.0% for TRZ. The ratio of bpCR rate was 1.259 and its 90% CI was 1.112-1.426, within the pre-defined equivalence margin. The difference of bpCR rate was 10.70% and its 95% CI was 4.13-17.26; the lower margin was contained within, the upper margin was outside the pre-defined equivalence margin. Secondary endpoints were comparable between SB3 vs TRZ: tpCR rate (45.8% vs 35.8%); ORR (96.3% vs 91.2%). Safety was comparable between SB3 vs TRZ during neoadjuvant period: incidence of treatment-emergent adverse events (96.6% vs 95.2%), most commonly neutropenia, alopecia, and nausea; incidence of serious adverse events (10.5% vs 10.7%). PK equivalence was demonstrated and immunogenicity between SB3 vs TRZ was comparable (0.7% vs 0.0%). Conclusions: Equivalence was demonstrated between SB3 and TRZ based on the ratio of bpCR rates. Safety, PK, and immunogenicity were similar. Complete safety and survival data will follow. Clinical trial information: NCT02149524.
Effect of incorporation of cisplatin to adjuvant chemotherapy for triple-negative breast cancer patients of unknown BRCA mutation status on survival.
Authors: Chia-Yen Hung, Ying-Wen Su, Ruey Kuen Hsieh, Hung-Bun Lam, Yuan-Ching Chang, Po-Sheng Yang
Journal: Journal of Clinical Oncology (2017)

e12009 Background: Recently, adding platinum to neoadjuvant chemotherapy (C/T) was associated with improved response rate in early Triple-negative breast cancer (TNBC). Whether incorporation of platinum to adjuvant C/T was associated clinical benefit has not been well investigated. Methods: Patients with resected TNBC who had available staging information and complete treatment at Mackay Memorial Hospital between 2004 and 2010 were enrolled for retrieving cllinical and pathologic information. Patients were monitored until death or Jan 2015. Statistical analysis was performed to determine the association of cancer-related overall survival (OS) and clinicopathological features. For stage I/II patients, 18 out of 115 received cisplatin-containing C/T. The mean OS for stage I/II patients with and without cisplatin-containing C/T was 6.05 years (standard error [SE]: 0.72 ) and 9.55 years (SE: 0.31), respectively ( P=0.07; log-rank test). For stage II/III patients, 20 out of 81 received cisplatin-containing C/T. The mean OS for stage II/III patients with and without cisplatin-containing C/T was 6.51 years (SE: 0.64) and 8.65 years (SE: 0.38), respectively ( P=0.56; log-rank test). In multivariate analysis for stage I-III patients, only age was significantly associated with OS (adjusted hazard ratio [HR]: 1.05; 95% confidence interval [CI]: 1.00-1.10). The adjusted HR for adding cisplatin to adjuvant C/T was 2.17 (95% CI: 0.729-6.44). Conclusions: In this small-numbered retrospective study, adding cisplatin to adjuvant C/T for TNBC with unknown BRCA mutation status did not have OS benefit. [Table: see text]